About: Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia
Creator	Cano, Antonio Baquedano, Laura Coronado, Pluvio Llaneza, Plácido Mendoza, Nicolás »more»
source	Elsevier; Medline; PMC
abstract	COVID-19 is associated with a systemic inflammatory response with activation of coagulation in symptomatic patients. The possibility of coagulopathies in peri- and postmenopausal women taking estrogen therapies makes it necessary to consider antithrombotic strategies, such as the use of low molecular weight heparins (LMWH) at specific prophylactic or treatment doses for each individual case, depending on the risk factors that each woman presents. For such reasons, a panel of experts from various Spanish scientific societies has met to develop usage recommendations for managing menopausal women taking menopausal hormone therapy (MHT) or combined hormonal contraception (CHC) during the COVID-19 pandemic.
has issue date	2020-05-06(xsd:dateTime)
bibo:doi	10.1016/j.maturitas.2020.04.019
bibo:pmid	32498938
has license	no-cc
sha1sum (hex)	f2f6b2aac3f899f00b3100cadef94f5b31ef3308
schema:url	https://doi.org/10.1016/j.maturitas.2020.04.019
resource representing a document's title	Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia
has PubMed Central identifier	PMC7200366
has PubMed identifier	32498938
schema:publication	Maturitas
resource representing a document's body	covid:f2f6b2aac3f899f00b3100cadef94f5b31ef3308#body_text
is schema:about of	named entity 'possibility' named entity 'activation' named entity 'postmenopausal' named entity 'specific' named entity 'TAKING' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software